Research demonstrates lower IL-6 levels in the cerebral cortex of aging diabetic rats treated with aminalon and succicard, indicating potential neuroinflammation reduction.
The study is devoted to studying the level and localization of interleukin-6 (IL-6) expression in the cerebral cortex of children aged 12 months. Type 1 diabetes mellitus (DM1) was modeled and at 18 months of age, GABA (aminalon) and succicard (a composition of phenotropil with succinic acid) were administered for 4 weeks. Immunohistochemical analysis revealed that IL-6 expression in the motor and retrosplenial cortex was higher in rats with DM1 compared with intact animals. In animals with DM 1, which were injected with the studied compounds (succicard and aminalon), IL-6 expression was lower, which may be due to their effect on neuroinflammation processes and the severity of diabetic encephalopathy. The purpose of the study: To characterize the expression of IL-6 in the cerebral cortex of 19-month-old rats with diabetic encephalopathy treated with aminalon and succicard for 4 weeks.
No takes yet. Share an insight, caveat, or question.
Смирнов et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: